

**TBLE e2. SUMMARY OF PROSPECTIVE STUDIES EVALUTING EFFECT OF RADIOACTIVE IODINE (RAI) TREATMENT ON THYROID EYE DISEASE (TED)**

<b>Study (follow-up time)</b>	<b>Treatment Arms</b>	<b>Development of TED disease (n, %)</b>	<b>Worsening of pre-existing TED disease (n, %)</b>	<b>Comments</b>
Bartalena et al 1989 <sup>60</sup> (1.5yrs )	26 pts RAI 26 pts RAI and steroids <sup>a</sup>	0 0	9 (56%) 0	
Tallstedt et al. 1992 <sup>60</sup> (2yrs) <sup>b</sup>	39 pts RAI 38 pts Methimazole 37 pts STT	nr nr nr	nr nr nr	13 (33%) <sup>c</sup> 4 (10%) 6 (16%)
Kung et al. 1994 <sup>61</sup> (2 yrs)	57 pts RAI 57 pts RAI and Methimazole	11 (27%) 10 (26%)	2 (12%) 4 (21%)	
Bartalena et al. 1998 <sup>49</sup> (1.5 yrs)	150 pts RAI 145 pts RAI and steroids <sup>a</sup> 148 pts Methimazole	6 (8%) 0 (0%) 1 (2)	17 (24%) 0 (0%) 3 (4%)	
Träisk et al. 2009 <sup>62</sup> (4 yrs)	163 pts RAI 150 pts Methimazole	53 (38%) 23 (18%)	10 (45%) 9 (47%)	

**ABBREVIATIONS**

TED: thyroid eye disease

RAI: radioiodine treatment

STT: subtotal thyroidectomy

nr: not reported

pts: patients

yrs: years

**NOTES:**

<sup>a</sup> For the initial month the oral prednisone dosage was 0.4-0.5 mg/kg, started 2-3 days after RAI and then tapered to discontinuation over the next 3 months.

<sup>b</sup> All patients were  $\geq 35$  years of age

<sup>c</sup> Study did not separate patients between progression and worsening of TED but rather the cumulative number of patients.